Frost & Sullivan ranks RapidAI's enterprise platform ahead of 96% in the industry

Get report
Skip to content

Frost & Sullivan ranks RapidAI's enterprise platform ahead of 96% in the industry

Get report
  • There are no suggestions because the search field is empty.
Request a Demo
Request a Demo

Core Capabilities

Featured

Radar metrics
BLOG The market has changed: Frost & Sullivan's 2026 Radar shows who's leading it RapidAI Chief Business Officer David Stoffel, MD, MBA, breaks down what this recognition signals — and what it means for health systems planning their AI strategy for the years ahead LEARN MORE
Platform overview
Request a Demo

RADIOLOGY SUPPORT

Neurovascular

Cardiac + vascular

LIFE SCIENCES

Featured

Cognitive Burden index RapidAI 2025
BLOG Radiology’s real challenge Read about the reality of cognitive burden LEARN MORE
Request a Demo

BUILT TO SUPPORT THE FULL SYSTEM

FEATURED

Resource_1600x900_C-Suite-Exec Insights_white paper
WHITE PAPER Empowering healthcare leaders with a deep clinical AI enterprise platform Learn how AI can address real-world challenges for administrators LEARN MORE
Overview
Request a Demo

Core Capabilities

Featured

Radiology Rewired podcast
PODCAST Season 1 available now Exploring how AI is transforming Radiology—one conversation at a time with clinicians and innovators LEARN MORE
Overview
Request a Demo

TRAINING & LEARNING

HELP & ASSISTANCE

Overview
Request a Demo

LEARN MORE ABOUT RAPIDAI

WORK WITH US

FEATURED

video thumbnail for dr Gregory Albers
VIDEO The story behind RapidAI Hear our founder, Greg Albers, MD, tell the history of how the company came to be Watch now
Company overview
Request a Demo
Press Release

RapidAI Receives FDA Clearance of Rapid LVO

For Identification of Suspected Large Vessel Occlusions

Share to

For Identification of Suspected Large Vessel Occlusions

Menlo Park, Calif. — August 13, 2020 –RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Rapid LVO has received Food and Drug Administration (FDA) clearance for detecting suspected LVOs (Large Vessel Occlusions). Rapid LVO helps physicians speed up triage or transfer decision-making. Working in as few as 3 minutes, Rapid LVO uses a vessel tracker in conjunction with assessment of brain regions with reduced blood vessel density to identify suspected LVOs with a sensitivity of 97% and a specificity of 96%. Stroke team members are also immediately notified when a suspected LVO is detected. “LVOs are the most disabling and deadly ischemic strokes,” said Dr. Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of RapidAI. “The ability to identify LVOs rapidly facilitates more effective treatment.  This is why we are very excited about the FDA clearance of Rapid LVO, a significant step forward in stroke diagnostics and care.” RapidAI makes the most-widely used stroke imaging software for patient care, research, and clinical trials—helping hospitals around the world save time, money, and lives. Rapid ® is the only clinically validated platform available and considered by many to be the gold standard for advanced cerebrovascular imaging. To learn more visit www.RapidAI.com/Rapid-CTA . About RapidAI RapidAI is the worldwide leader in advanced imaging for stroke. Based on intelligence gained over 1,000,000 scans from more than 1,600 hospitals in over 50 countries, the Rapid ® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview ® , a comprehensive aneurysm management platform. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically-proven, data-driven technology. With our validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day.

Contact PR

Jessica Stebing

Jessica Stebing

Group Manager, Marketing Communications

stebing@rapidai.com